BioPharmSignal logoBioPharmSignal

Biotech News

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Entera Bio (ENTX)Entera BioClinical readout

Post-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia)

Related news

ENTXEntera Bio2026-08-04 12:30 EST

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

ENTXEntera Bio2026-10-08 12:00 EST

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

RXRXRecursion2026-11-02 21:25 EST

New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

RHHBYRoche Holdings AG2026-10-21 12:00 EST

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

STTKShattuck Labs2026-06-05 20:05 EST

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

IBIOIbio Inc2026-06-02 11:00 EST

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

APGEApogee Therapeutics2026-05-27 10:31 EST

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

APGEApogee Therapeutics2026-05-27 10:30 EST

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

PHARPharming Group2026-09-22 05:00 EST

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

View all latest news

Entera Bio

Oral Peptide Delivery Entera Bio develops oral formulations of peptides and proteins that have traditionally required injection. Its proprietary N-Tab platform is designed to improve intestinal absorption in a convenient tablet form. EB613 Osteoporosis Program EB613 is an oral parathyroid-hormone peptide candidate intended to provide...

Recent company news

ENTXEntera Bio2026-10-13 11:00 EST

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

ENTXEntera Bio2026-10-08 12:00 EST

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

ENTXEntera Bio2026-10-06 12:00 EST

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

ENTXEntera Bio2026-08-27 13:44 EST

Correction: Entera to Participate in Upcoming Fall Investor Conferences

ENTXEntera Bio2026-08-27 12:00 EST

Entera to Participate in Upcoming Fall Investor Conferences

Stock data

Close
2.99 USD
Market cap
61.53M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States